Clinical trials in St Germain En Laye – page 83

3 345 clinical trials in St Germain En Laye, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

St Germain En Laye at a glance

3 345

clinical trials

Research sites1

Quick filters

3 345 trials in St Germain En Laye

Open in trial search

Perinatal depression

Recruiting

Study on Treating Anemia After Cesarean with Ferric Carboxymaltose or Oral Iron in Women with Moderate Iron Deficiency Anemia

Registered drugNo placebo

Study on Treating Anemia After Cesarean with Ferric Carboxymaltose or Oral Iron in Women with Moderate Iron Deficiency Anemia

Registered drugNo placebo

France

Participants:18–64 years
Substances:Ascorbic Acid
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Rectal cancer

Recruiting

Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

Registered drugNo placebo

Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Institut Regional Du Cancer De Montpellier

Contact Research Centre

Neoplasm+5

Recruiting

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Registered drugNo placebo

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:AstraZeneca AB

Contact Research Centre

Factor VIII deficiency

Recruiting

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo

Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Efanesoctocog Alfa
Sponsor:Swedish Orphan Biovitrum AB (publ)

Contact Research Centre

Joint stabilisation

Recruiting

Study Comparing Rivaroxaban and Drug Combination for Preventing Blood Clots in Patients with Lower Limb Injuries Requiring Immobilization

Registered drugNo placebo

Study Comparing Rivaroxaban and Drug Combination for Preventing Blood Clots in Patients with Lower Limb Injuries Requiring Immobilization

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dalteparin Sodium
Sponsor:Centre Hospitalier Universitaire D'Angers

Contact Research Centre

Breast cancer

Recruiting

Study on 68Ga-FAPI-46 for Predicting Treatment Response in Early-Stage High-Risk Triple-Negative Breast Cancer Patients Undergoing Chemo-Immunotherapy

Registered drugNo placebo

Study on 68Ga-FAPI-46 for Predicting Treatment Response in Early-Stage High-Risk Triple-Negative Breast Cancer Patients Undergoing Chemo-Immunotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Institut Curie

Contact Research Centre

Lymphoma+6

Recruiting

Study of Tulmimetostat (CPI-0209) for Patients with Advanced Solid Tumors and Lymphomas

Registered drugNo placebo

Study of Tulmimetostat (CPI-0209) for Patients with Advanced Solid Tumors and Lymphomas

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Neoplasm

Recruiting

Study of AZD3470 alone and in combination with other cancer drugs for patients with advanced solid tumors that are MTAP deficient

Registered drugNo placebo

Study of AZD3470 alone and in combination with other cancer drugs for patients with advanced solid tumors that are MTAP deficient

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:AZD3470
Sponsor:AstraZeneca AB

Contact Research Centre

Osteochondrodysplasia

Recruiting

Study on the Safety and Effectiveness of TransCon CNP for Infants with Achondroplasia

Investigational

Study on the Safety and Effectiveness of TransCon CNP for Infants with Achondroplasia

Investigational

France

Participants:0–17 years
Substances:Navepegritide
Sponsor:Ascendis Pharma Growth Disorders A/S

Contact Research Centre

Haematological malignancy+1

Recruiting

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors

InvestigationalNo placebo

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Zilovertamab Vedotin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Aveo Pharmaceuticals Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in St Germain En Laye

What the registry says about research in the country

01 Hematologic Oncology

Investigating innovative combination therapies for follicular lymphoma, comparing mosunetuzumab plus lenalidomide against standard treatments to improve progression-free survival in previously untreated patients.

Advanced lymphoma treatments
Targeted therapy combinations
Novel therapeutic approaches

Research focuses on enhancing treatment outcomes for high-risk lymphoma patients.

02 Breast Cancer Research

Evaluating treatment strategies for elderly women with HER2-negative breast cancer, examining the effectiveness of combined chemotherapy and hormone therapy based on genomic profiling.

Age-specific treatment protocols
Personalized therapy approaches
Genomic-guided interventions

Studies aim to optimize treatment outcomes for senior patients while considering their specific needs.

03 Neurological Disorders

Investigating treatment optimization for Secondary Progressive Multiple Sclerosis patients, focusing on the safety and efficacy of disease-modifying therapy withdrawal in stable patients over 50.

Treatment discontinuation studies
Age-specific MS management
Long-term disease monitoring

Research aims to enhance quality of life while maintaining disease stability.

04 Maternal Health

Examining preventive strategies for pregnancy-associated hypertension and pre-eclampsia through controlled trials of acetylsalicylic acid treatment in pregnant women with chronic hypertension.

Maternal-fetal outcomes
Preventive interventions
Pregnancy complications

Focus on reducing maternal and fetal morbidity through preventive care.

05 Endocrine Surgery

Investigating the effects of preoperative cholecalciferol supplementation on post-thyroidectomy outcomes, specifically focusing on preventing hypocalcemia complications.

Surgical outcome optimization
Preventive supplementation
Post-operative care

Research aims to improve patient recovery and reduce hospital stays after thyroid surgery.

Back to France All countries